La thérapie actuelle du rhabdomyosarcome orbitaire de l'enfant [Update of orbital rhabdomyosarcoma therapy in children]

Détails

ID Serval
serval:BIB_89243A1BF6EC
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
La thérapie actuelle du rhabdomyosarcome orbitaire de l'enfant [Update of orbital rhabdomyosarcoma therapy in children]
Périodique
Journal français d'ophtalmologie
Auteur(s)
Ducrey N., Nenadov-Beck M., Spahn B.
ISSN
0181-5512
Statut éditorial
Publié
Date de publication
2002
Peer-reviewed
Oui
Volume
25
Numéro
3
Pages
298-302
Langue
français
Notes
Publication types: Comparative Study ; English Abstract ; Journal Article ; Research Support, Non-U.S. Gov't - Publication Status: ppublish
Résumé
INTRODUCTION: Rhabdomyosarcoma is the most frequent primitive orbital malignant tumor in children. If the treatment is started as soon as possible after discovery of the disease, the vital prognosis is considerably better than otherwise. The goal of this paper is to present the new therapeutic protocol and to report our experience in this field. MATERIAL AND METHOD: During the past 35 years, 102 cases of orbital tumors were collected in children under 15 years of age: 5 cases of rhabdomyosarcoma were cared for in our department. At the time of tumor diagnosis, the age of our patients ranged from 3 weeks to 13 years. After a biopsy or excision biopsy, all our cases were treated by chemotherapy with or without radiotherapy. Medication was mostly vincristine, ifosfamide and actinomycine D. When the result of the treatment was not satisfactory, carboplatine and epirubicine, vincristine as well as ifosfamide were given. Radiotherapy was performed only in particular cases or in recurrences. CONCLUSION: Rhabdomyosarcoma is a highly malignant tumor. Although rare, it is the most frequent of malignant tumors in children. It is important to keep it in mind in order to perform a biopsy enabling quick diagnosis and treatment following the modern protocol giving the highest chances of survival to these patients: about 98% in 3 years.
Mots-clé
Adolescent, Age Factors, Antineoplastic Combined Chemotherapy Protocols, Biopsy, Child, Child, Preschool, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Infant, Infant, Newborn, Magnetic Resonance Imaging, Male, Orbit, Orbital Neoplasms, Radiotherapy Dosage, Rhabdomyosarcoma, Time Factors
Pubmed
Web of science
Création de la notice
20/03/2008 9:34
Dernière modification de la notice
20/08/2019 14:48
Données d'usage